Treatment for adults with Ph-negative ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a less intensive but continuous treatment approach for adults newly diagnosed with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to improve outcomes by using minimal residual disease (MRD) to guide therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 55 years old
- Newly diagnosed with Philadelphia chromosome-negative (Ph-negative) ALL
- Have not received any prior treatment for ALL
- Not have Philadelphia chromosome-positive (Ph-positive) ALL
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a lower dose of chemotherapy followed by 14 days of blinatumomab for adults newly diagnosed with a type of leukemia called B-ALL. The goal is to see if this approach works well and reduces side effects.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
Hear when a new Precursor Cell Lymphoblastic Leukemia-Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.